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Liver Transplantation

Portopulmonary Hypertension: A Survey of
Practice Patterns and Provider Attitudes
Hilary M. DuBrock, MD,1 Reena J. Salgia, MD,2 Norman L. Sussman, MD,3
Sonja D. Bartolome, MD,4 Zakiyah Kadry, MD,5 David C. Mulligan, MD,6 Sarah Jenkins, MS, 7
Kandace Lackore, BS, 7 Richard N. Channick, MD,8 Steven M. Kawut, MD, MS,9 and Michael J. Krowka, MD1

Background. The role of liver transplantation (LT) in the management of portopulmonary hypertension (POPH) is poorly
understood. The aim of this study was to better understand provider attitudes and practice patterns regarding the management of patients with POPH and to assess the concordance between clinical practice and current guidelines. Methods.
We performed a multicenter survey study of hepatologists and pulmonary hypertension (PH) physicians at US LT centers that
performed >50 transplants per year. Survey responses are summarized as number (%). Associations were assessed using
a Wilcoxon-rank sum, chi-square, or Fisher exact test, as appropriate. Results. Seventy-four providers from 35 centers
were included. There was marked variability regarding screening practices, management, and attitudes. Forty-two percent
responded that POPH nearly always or often improves with LT, and 15.5% reported that POPH rarely or never improves. In
contrast to current guidelines, 50.7% agreed that treated POPH should be an indication for LT in patients with compensated
cirrhosis. Hepatologists were more likely than PH physicians to agree that POPH should be an indication for LT (P = 0.02).
Forty-nine percent of respondents thought that the current POPH Model for End-stage Liver Disease exception criteria
should be modified, and management of patients with an elevated mean pulmonary arterial pressure and normal pulmonary
vascular resistance differed from current policies. Conclusions. There is marked variability in provider attitudes and
practice patterns regarding the management of POPH. This study highlights the need for prospective studies to inform
practice and for improved implementation of practice guidelines in order to standardize care.
(Transplantation Direct 2019:5: e456; doi: 10.1097/TXD.0000000000000900. Published online 22 May, 2019.)

P

ortopulmonary hypertension (POPH), pulmonary arterial hypertension (PAH) that develops in the setting of
portal hypertension, affects 5%–6% of liver transplantation
(LT) candidates.1,2 POPH is a progressive condition that can
lead to right heart failure and death.3,4 Without PAH therapy
or LT, survival in POPH is poor, but there are little prospective
data to guide decisions regarding medical treatment and the
appropriate timing of LT.5,6
In order to expedite LT, patients with treated POPH who
meet certain hemodynamic criteria (mean pulmonary arterial
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pressure [mPAP] <35 mm Hg and pulmonary vascular resistance [PVR] <400 dynes ⋅ sec ⋅ cm5 [5 Wood units]) are eligible
for a Model for End-stage Liver Disease (MELD) exception
or waitlist priority upgrade.7 These criteria were developed in
2006 on the basis of predominantly single-center retrospective
studies and before the approval of many currently available
PAH therapies.3 Despite these criteria, however, misclassification of patients with POPH MELD exceptions is common.8
Recently, studies have also identified significant predictors of
mortality in POPH, but these characteristics are not included
in the current MELD exception criteria.9,10
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Practice guidelines were published by the International
Liver Transplant Society in July 2016 regarding the diagnosis
and management of POPH, but acceptance of these guidelines
and the concordance between published guidelines and clinical practice are not known.3 The aims of this study were to
better understand the attitudes and practice patterns of hepatologists and PH providers, to assess the concordance between
guidelines and clinical practice, and to assess provider attitudes regarding the POPH MELD exception policy to aid in
determining whether this policy should be revised. Because
POPH is a relatively uncommon disease with little evidence to
guide management, we hypothesized that there would be significant variation in physician knowledge and practice regarding the care of patients with POPH.

MATERIALS AND METHODS
We performed a cross-sectional mixed qualitative and
quantitative multicenter survey-based study of a convenience sample of physicians at liver transplant centers
in the United States. Centers that performed >50 liver
transplants in 2016–2017 according to the Scientific
Registry of Transplant Recipients were included (n = 58).
Hepatologists and pulmonary hypertension (PH) providers
(cardiologists or pulmonologists) at each center were surveyed. Transplant surgeons were also included in the initial
survey, but their responses are reported in Supplemental
Materials (SDC, http://links.lww.com/TXD/A211) due to
a low response rate. Physicians were identified from review
of the center’s website, and email addresses were obtained
when possible from an internet search or the member
directories for the American Association for the Study of
Liver Diseases or Pulmonary Hypertension Association.
The survey was administered in August 2017, 1 year after
the International Liver Transplant Society guidelines were
published. Responses are reported by specialty (hepatology
versus PH) and as a total number of responses when no
significant differences were identified between specialties.
United Network for Organ Sharing (UNOS) regions were
categorized by the median MELD at transplant into low
MELD (regions 3, 6, 10, and 11), mid MELD (regions 2, 4,
7, and 8), and high MELD (regions 1, 5, and 9) groups as
previously described for comparison, because experiences
and attitudes regarding POPH at centers with a higher
median MELD at transplant (and consequently a longer
waitlist time for patients with MELD exceptions) may be
different when compared with centers with a lower median
MELD at transplant.11 Responses from providers at larger
transplant centers (100 or more LTs per year according
to the Scientific Registry of Transplant Recipients) versus
smaller LT centers were also compared.
The survey was designed by a multidisciplinary working
group (H.M.D., R.J.S., M.J.K., N.L.S., S.D.B., Z.K., D.C.M.,
R.N.C., and S.M.K.) with representation from hepatologists, pulmonologists, and transplant surgeons and was
administered via an email link by the Mayo Clinic Survey
Research Center using Qualtrics software (Qualtrics, Provo,
UT). Survey questions included basic demographic information as well as questions concerning physician attitudes and
practices regarding the management of POPH. Branching
logic was used to display selected questions on the basis of
specialty or prior survey responses as detailed in the survey

questions in the Supplemental Materials (SDC, http://links.
lww.com/TXD/A211).
Statistical Analysis
Descriptive data are reported as number (%). Associations
between survey responses and respondent characteristics
were assessed using a Wilcoxon-rank sum, chi-square, or
Fisher exact test, as appropriate. A two-sided P < 0.05 was
considered statistically significant. All data were analyzed in
SAS, version 9.4. The study was approved by the Mayo Clinic
Institutional Review Board.

RESULTS
Thirty-five of 58 (60.3%) transplant centers from UNOS
regions 1–8, 10, and 11 were represented in the survey.
There was a range of 1–6 respondents per center. Thirty-nine
respondents were from larger LT centers (100 or more LTs
per year), while 35 were from smaller LT centers (50–100 LTs
per year). The overall response rate for the survey was 20.6%
(82 out of 399 providers). Response rate varied by specialty
(P < 0.001) with a response rate of 41.1% for cardiology/
pulmonary providers and 17.5% for hepatologists and 9.4%
for transplant surgeons. All hepatologists reported additional
training or expertise in transplant hepatology. Due to the low
response rate among transplant surgeons with a high likelihood of bias, their responses are not included in the manuscript
but are included in the Supplemental Materials (SDC, http://
links.lww.com/TXD/A211). A detailed description of survey
respondent characteristics is included in Table 1.
Screening for POPH
There was marked variability in hepatology practice regarding screening for POPH in LT candidates (Table 2). Compared
to hepatologists from larger LT centers, hepatologists from
TABLE 1.

Survey respondent characteristics
Characteristic

Total
(n = 74)

Male
51 (69.9)
Age
31–40 y
24 (32.4)
41–50 y
30 (40.5)
51–60 y
13 (17.6)
61+ y
7 (9.5)
United Network for Organ Sharing
Region
  1
3 (4.2)
  2
10 (13.9)
  3
7 (9.7)
  4
4 (5.6)
  5
11 (15.3)
  6
6 (8.3)
  7
12 (16.7)
  8
4 (5.6)
  9
0 (0.0)
  10
5 (6.9)
  11
10 (13.9)

Hepatologists
(n = 44)

PH providers
(n = 30)

34 (79.1)

17 (56.7)

15 (34.1)
18 (40.9)
8 (18.2)
3 (6.8)

9 (30.0)
12 (40.0)
5 (16.7)
4 (13.3)

0 (0.0)
5 (11.9)
3 (7.1)
2 (4.8)
9 (21.4)
5 (11.9)
7 (16.7)
3 (7.1)
0 (0.0)
3 (7.1)
5 (11.9)

3 (10.0)
5 (16.7)
4 (13.3)
2 (6.7)
2 (6.7)
1 (3.3)
5 (16.7)
1 (3.3)
0 (0.0)
2 (6.7)
5 (16.7)

Frequencies not adding to 44 hepatologists indicate missing data.
PH, pulmonary hypertension.

P
0.07
0.55
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TABLE 2.

Survey questions and responses
Survey questions
Screening for POPH
Which of the following best describes your center’s practice related to screening liver transplant candidates for
POPH? Mark all that apply
Annual transthoracic echocardiograms
Transthoracic echocardiogram once for screening and then again on a variable interval
Transthoracic echocardiogram once for screening and then again as indicated by new signs or symptoms
All patients are seen by pulmonary or cardiology as part of their routine pretransplant evaluation
Patients are referred to pulmonary or cardiology only if they have an abnormal echocardiogram or symptoms
Other
In an asymptomatic individual with normal RV size and function on echocardiogram, when would you refer a liver
transplant candidate for further evaluation of POPH?
Estimated RVSP >30 mm Hg
Estimated RVSP >35 mm Hg
Estimated RVSP >40 mm Hg
Estimated RVSP >50 mm Hg
In an asymptomatic individual with RV dilatation or dysfunction on echocardiogram, when would you refer a liver
transplant candidate for further evaluation of POPH?
I would refer regardless of RVSP
Estimated RVSP >30 mm Hg
Estimated RVSP >35 mm Hg
Estimated RVSP >40 mm Hg
Estimated RVSP >50 mm Hg
Attitudes regarding the current MELD exception for POPH
The following aspects of the current MELD exception for POPH should be modified. Mark all that apply.
The hemodynamic criteria for an initial diagnosis of moderate-to-severe POPH
The hemodynamic criteria for adequate response to PAH therapy
Need for right heart catheterization every 3 mo
Lack of specific criteria regarding liver disease severity
Lack of specific criteria regarding right ventricular function
None of the above
Other
Which of the following do you consider an absolute contraindication to liver transplantation? Mark all that apply.
mPAP >50 mm Hg
mPAP >35 mm Hg regardless of PVR
mPAP >35 mm Hg with an elevated PVR > 240 dynes-s-cm-5
mPAP >35 mm Hg with an elevated PVR > 400 dynes-s-cm-5
PVR >240 dynes-s-cm-5 (3 Wood units) regardless of mPAP
PVR >400 dynes-s-cm-5 (5 Wood units) regardless of mPAP
None of the above
Unsure
What is your center’s approach to a patient with an approved POPH MELD exception on PAH therapy who
develops an elevated mPAP >35 mm Hg due to a high cardiac output with a normal PVR on follow-up right
heart catheterization?
Inactivate from waitlist until pulmonary arterial pressure improves
Remove from waitlist
Submit an appeal
Unsure
Other
Management of POPH
For treatment of POPH in LT candidates, my center uses which of the following classes of pulmonary arterial
hypertension targeted therapy. Mark all that apply.
Phosphodiesterase 5 inhibitors
Endothelin receptor antagonists
Inhaled prostacyclin analogues
Parenteral prostacyclin analogues
Oral prostacyclin analogues or IP receptor agonists
Soluble guanylate cyclase stimulators
Calcium channel blockers

Total

Hepatologists
(n = 44)

PH
(n = 30)

N/A
N/A
N/A
N/A
N/A
N/A

22 (50.0)
14 (31.8)
8 (18.2)
7 (15.9)
12 (27.3)
2 (4.5)

N/A
N/A
N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A

3 (8.1)
13 (35.1)
14 (37.8)
7 (18.9)

N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A

23 (62.2)
4 (10.8)
5 (13.5)
3 (8.1)
2 (5.4)

N/A
N/A
N/A
N/A
N/A

12 (16.2)
21 (28.4)
27 (36.5)
23 (31.1)
38 (51.4)
9 (12.2)
7 (9.5)

3 (6.8)
6 (13.6)
12 (27.3)
14 (31.8)
21 (47.7)
8 (18.2)
2 (4.5)

9 (30.0)
15 (50.0)
15 (50.0)
9 (30.0)
17 (56.7)
1 (3.3)
5 (16.7)

0.01
0.001
0.05
1.00
0.49
0.07
0.11

56 (75.7)
4 (5.4)
32 (43.2)
57 (77.0)
8 (10.8)
37 (50.0)
0 (0.0
4 (5.4)

33 (75.0)
4 (9.1)
23 (52.3)
30 (68.2)
5 (11.4)
17 (38.6)
0 (0.0
2 (4.5)

23 (76.7)
0 (0.0)
9 (30.0)
27 (90.0)
3 (10.0)
20 (66.7)
0 (0.0
2 (6.7)

1.00
0.14
0.09
0.047
1.00
0.03
1.00
1.00
0.02

30 (44.8)
0 (0.0)
19 (28.4)
11 (16.4)
7 (10.4)

22 (57.9)
0 (0.0)
8 (21.1)
3 (7.9)
5 (13.2)

8 (27.6)
0 (0.0)
11 (37.9)
8 (27.6)
2 (6.9)

N/A
N/A
N/A
N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A
N/A
N/A

27 (90.0)
25 (83.3)
18 (60.0)
29 (96.7)
14 (46.7)
11 (36.7)
2 (6.7)

P

Continued next page
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TABLE 2. (Continued)

Survey questions and responses
Survey questions

Total

Posttransplant, pulmonary arterial hypertension targeted therapy should be weaned based on which of the following?
Symptoms alone
N/A
Symptoms and serial right heart catheterizations
N/A
Symptoms and serial echocardiograms
N/A
Symptoms, serial echocardiograms, and serial right heart catheterizations
N/A
Pulmonary arterial hypertension targeted therapy should not be weaned posttransplant
N/A
Beta-blocker use should be minimized in patients with POPH
Strongly agree
11 (16.7)
Agree
26 (39.4)
Neutral
22 (33.3)
Disagree
6 (9.1)
Strongly Disagree
1 (1.5)
Elective TIPS should be avoided in patients with severe POPH
Strongly agree
40 (60.6)
Agree
18 (27.3)
Neutral
8 (12.1)
Disagree
0 (0.0)
Strongly disagree
0 (0.0)

Hepatologists
(n = 44)

PH
(n = 30)

N/A
N/A
N/A
N/A
N/A

0 (0.0)
1 (3.4)
7 (24.1)
20 (69.0)
1 (3.4)

7 (18.9)
14 (37.8)
14 (37.8)
2 (5.4)
0 (0.0)

4 (13.8)
12 (41.4)
8 (27.6)
4 (13.8)
1 (3.4)

27 (73.0)
9 (24.3)
1 (2.7)
0 (0.0)
0 (0.0)

13 (44.8)
9 (31.0)
7 (24.1)
0 (0.0)
0 (0.0)

P

0.50

0.01

P values are reported for comparison (Fisher exact or Wilcoxon-rank sum, as appropriate) of responses from hepatologists versus PH providers. Frequencies not adding to 44 hepatologists or 30
pulmonary hypertension providers indicate missing data. P values < 0.05 are noted in bold.
LT, liver transplantation; MELD, Model for End-stage Liver Disease; mPAP, mean pulmonary arterial pressure; N/A, not applicable; PH, pulmonary hypertension; PAH, pulmonary arterial hypertension; POPH,
portopulmonary hypertension; PVR, pulmonary vascular resistance; RVSP, right ventricular systolic pressure; TEE, transesophageal echocardiogram; TIPS, transjugular intrahepatic portosystemic shunt.

smaller LT centers were more likely to perform annual
echocardiograms for screening (42.9% versus 17.9%, P =
0.02). Among hepatologists, there was variability in terms
of an estimated right ventricular systolic pressure (RVSP)
that would trigger further evaluation (specialty referral or
right heart catheterization) of POPH in an asymptomatic LT
candidate with normal right ventricular (RV) size and function (Table 2). In the presence of RV dilation or dysfunction,
however, most hepatologists (62%, Table 2) would refer these
patients for further testing regardless of RVSP.
Attitudes Regarding LT and POPH
There was variability in attitudes regarding the safety and
outcomes of treated POPH with LT (Figure 1). Forty-two percent responded that POPH nearly always or often improves
with LT, while 15.5% reported that POPH rarely or never
improves with LT (Figure 1). Perceptions regarding POPH as
a condition that improves with LT varied by UNOS region
category (P = 0.03). Respondents from regions with a higher

median MELD at transplant were less likely to respond that
POPH nearly always or often improves with LT. There was
also variability in opinions regarding POPH as an indication
for LT in compensated cirrhosis (Figure 2), and attitudes differed by specialty (P = 0.01). Sixty-four percent of hepatologists and 31.0% of PH providers agreed that treated POPH
should be an indication for LT in patients with compensated
cirrhosis and a MELD score ≤12. More respondents overall
agreed that POPH should be an indication for LT in patients
with decompensated cirrhosis (83.1% in decompensated versus 50.7% in compensated cirrhosis, P < 0.001) (Figure 2).
There was no difference in attitudes of providers at larger versus smaller LT centers (P > 0.05).
Experience With LT in POPH
Seventy-two percent of respondents described their experience with LT in patients with POPH as overall favorable,
and all responded that they had prior experience with LT
in patients with POPH. Opinions regarding the safety of LT

FIGURE 1. Attitudes regarding POPH and liver transplantation. There was variability in attitudes of hepatologists and PH providers regarding the

safety and outcomes of liver transplantation in patients with treated POPH. PH, pulmonary hypertension; POPH, portopulmonary hypertension.
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FIGURE 2. POPH as an indication for LT. There was variability in attitudes regarding POPH as an indication for LT. More respondents thought

that POPH should be an indication for LT in patients with decompensated vs compensated cirrhosis (P < 0.001). Hepatologists were more
likely than PH providers to agree that POPH should be an indication for LT in compensated cirrhosis. LT, liver transplantation; PH, pulmonary
hypertension; POPH, portopulmonary hypertension.

were significantly impacted by prior experience. Respondents
with a favorable experience were more likely to answer that
LT was nearly always or often safe (35/49, 71.4%) as compared to respondents with either neutral (8/14, 57.1%) or
unfavorable experiences (0/4, 0%) (P = 0.01). The majority of
respondents (76.8%) reported prior experience with LT being
canceled at the time of surgery due to the presence of PH with
a range of 1–10 canceled liver transplants per respondent
(average 3.3). In most cases, PH was newly detected at the
time of planned transplant.
Attitudes Regarding the Current MELD Exception
for POPH
Almost half of respondents (49.3%) agreed that the current
MELD exception criteria for POPH should be modified while
32.8% were neutral and 17.9% disagreed (Figure 3). Specific
aspects of the POPH MELD exception criteria that respondents thought should be modified are detailed in Table 2.
Providers from smaller LT centers were more likely than providers from larger LT centers to agree that there should be
specific criteria regarding liver disease severity (45.7% versus 17.9%, P = 0.01). Other responses regarding the POPH
MELD exception did not differ by center size (P > 0.05). More
PH providers than hepatologists (P = 0.001) thought that the
hemodynamic criteria for response to PAH therapy should be

modified (Table 2). Other suggested modifications included
implementation of specific regional criteria to facilitate timely
transplant, a need for improved phenotyping of patients with
POPH, higher prioritization for patients with POPH on PAH
therapy for a longer period of time and modification of the
criteria, so mPAP was not the primary determinant of eligibility with the need to properly define an elevated mPAP due to
a high flow state.
The approach to a patient with treated POPH and an
elevated mPAP >35 mm Hg due to a high cardiac output
with a normal PVR varied by specialty (P = 0.02) (Table 2).
Individualized approaches to this scenario included aggressive
diuresis or ultrafiltration, repeat right heart catheterization,
lowering the dose of PAH therapy, and trying to reduce the
cardiac output with midodrine. Only 5.4% of respondents
thought that an mPAP >35 mm Hg regardless of PVR should
be an absolute contraindication to LT (Table 2) and more
PH providers than hepatologists thought that an mPAP >35
mm Hg with an elevated PVR >400 dynes was a contraindication to LT (P = 0.047) (Table 2).
Management of POPH
Most respondents agreed that liver transplant candidates
with moderate-to-severe POPH should be managed in centers
with expertise in POPH (Table 2). Most responses regarding
beta-blocker use and transjugular intrahepatic portosystemic
shunt in POPH were concordant with current guidelines
(Table 2). PH providers were asked additional questions regarding PAH therapy. Treatment with PAH therapy was diverse,
spanning the spectrum from oral to inhaled to parenteral
therapy. No particular therapeutic class emerged as a favored
approach to treatment (Table 2). One respondent reported
using calcium channel blockers for treatment of POPH despite
current guidelines that recommend avoiding their use in POPH.
Providers had varied experience with weaning and discontinuing PAH therapy posttransplant, with some reporting that
they nearly always weaned or discontinued PAH therapy and
others reporting that they rarely or never weaned or discontinued PAH therapy (Figure 4). The approach to weaning therapy
also varied among PH providers (Table 2).

DISCUSSION
FIGURE 3. Attitudes regarding the current MELD exception for

POPH. Almost half of all respondents (49.3%) thought that the current
MELD exception criteria for POPH should be modified. MELD, model
for end stage liver disease; PH, pulmonary hypertension; POPH,
portopulmonary hypertension.

We performed the first multidisciplinary survey of transplant hepatologists and PH providers to better understand
their attitudes and practice patterns regarding the management of POPH and to compare current practice to clinical
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FIGURE 4. PAH therapy. There was variability in hepatologist and PH provider responses regarding weaning and discontinuation of PAH
therapy posttransplant. PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.

guidelines. We found that there was marked variability in
management, and nearly half thought that the current POPH
MELD exception criteria should be modified. Additionally, in
contrast to current guidelines, many agreed that POPH should
be an indication for LT, even in the setting of compensated cirrhosis. This study highlights the need for prospective studies
to address evidence gaps and inform clinical practice and for
improved understanding of barriers to adoption of guidelines
in order to standardize care for patients with POPH.
Survey Respondents
We chose to study hepatologists and PH providers, as these
physicians are involved in the management of POPH regardless of whether they are LT candidates. Other specialists, such
as transplant anesthesiologists, play a critical role in the perioperative management of LT candidates with POPH but are
not typically involved in the long-term management of POPH,
so they were not included. We also surveyed transplant surgeons but did not include their responses in the article due to
the low response rate. All of the respondents reported prior
experience with LT in POPH. Although this may be due to
response bias, this suggests that most providers at large LT
centers manage patients with POPH and that the respondents
in our survey were equipped to answer questions regarding
POPH management.
Although the response rate for the survey was low, there
was a wide spectrum of responses, reflecting a diverse range
of attitudes and practice of both hepatologists and PH providers from 35 LT centers across the country with representation from 10/11 UNOS regions. Although our results may not
be representative of all hepatologists and PH providers, this
study is the first to provide insight into the diverse attitudes
and practice of providers from across the country.
Screening for POPH
In concordance with current guidelines,12 most transplant hepatologists perform screening echocardiograms at
the time of LT evaluation. In the setting of insufficient data
to guide the need for invasive testing, however, there was
marked variability among hepatologists in the estimated
RVSP that would prompt further workup of POPH, ranging
from >30 to >50 mm Hg. This variability in practice may
lead to overutilization of invasive testing at some institutions

and inadequate recognition or delayed diagnosis of POPH
at other centers.
A high percentage of respondents reported prior experience with canceled liver transplants, predominantly due to the
presence of newly detected PH. This suggests that improved
screening practices are needed in order to identify and treat
these patients prior to LT. Due to inadequate evidence, current guidelines are vague regarding optimal time intervals and
indications for subsequent echocardiograms in waitlisted LT
candidates.3,12 Multicenter prospective studies to better understand clinical risk factors for POPH and its rate of development and progression could help inform evidence-based
screening practice and guidelines.
Attitudes and Experience Regarding LT and POPH
There was variability in attitudes regarding the safety of LT
in patients with POPH and the expected posttransplant outcomes. In an effort to better understand reasons for this variability, we found that attitudes regarding safety were impacted
by a provider’s prior experience with LT in POPH (favorable
versus unfavorable). We also observed that respondents from
regions with a higher median MELD at transplant were less
likely to respond that POPH improves with LT. One possible explanation for this finding is that patients with POPH
MELD exceptions have longer waitlist times in regions with
a higher median MELD at LT and may have less reversible
disease at the time of LT.
The most recent guidelines state that the unpredictability
of post-LT outcomes precludes POPH from being considered an indication for LT,3 but half of respondents thought
that POPH should be an indication for LT in patients with
compensated cirrhosis, and the majority thought that POPH
should be an indication for LT in decompensated cirrhosis.
This disparity between current guidelines and provider attitudes highlight the need for better understanding of longterm outcomes in patients with POPH as well as factors that
influence provider attitudes. This is especially important
given the scarcity of organs and the unknown long-term
survival benefit of LT in patients with POPH. Although several recent studies have been published regarding long-term
outcomes of POPH with LT, findings and conclusions from
these studies are conflicting.13-16 Savale et al13 reported 77%
survival 3 years post-LT and concluded that stabilization or
improvement of POPH was possible with the combination

© 2019 Wolters Kluwer

of PAH therapy and LT, while Verma et al reported 53.8%
5-year post-LT survival with the majority of deaths occurring within the first 6 months and concluded that POPH in
isolation should no longer be a valid consideration to LT.16
We identified several significant differences between hepatologists and PH providers regarding attitudes and management which highlight the need for improved communication
and integration of care among specialists. For example, hepatologists were more likely than PH providers to agree that
POPH should be an indication for LT in compensated cirrhosis. The reasons for this are not known but could be due
to differences in opinion regarding the reversibility of POPH
with LT or differences in awareness of the efficacy of current
PAH therapy.
Attitudes Regarding the Current MELD Exception
for POPH
Responses regarding the POPH MELD exception policy
were insightful, and we hope that this study can provide
groundwork for future efforts to examine and revise the
current POPH MELD exception policy. Respondents highlighted several key issues with the current MELD exception
policy for POPH. (1) More respondents agreed that POPH
should be an indication for LT in decompensated cirrhosis
rather than compensated cirrhosis. Prior studies have also
found that MELD score significantly impacts waitlist mortality risk.9 Despite this, there is no liver disease severity
requirement as part of the current MELD exception criteria.
(2) Half of respondents thought there should be specific criteria regarding RV function as part of the MELD exception
criteria. Although preserved RV function is essential to the
safety of LT, it has not been well studied in POPH, and it is
not clear how RV function should be defined or what thresholds should preclude LT. (3) A third and major issue concerned successful response to PAH therapy. It is clear from
responses that the clinical scenario of high-flow–mediated
elevations in mPAP should be addressed as provider attitudes and practice differed markedly from current policies.
Although a posttreatment mPAP <35 mm Hg is required
for MELD exception eligibility, only 5.4% of respondents
thought that an mPAP >35 mm Hg regardless of PVR should
be an absolute contraindication to LT. The approach to a
patient with treated POPH and an elevated mPAP due to a
high cardiac output also varied with some providers stating they would perform interventions, such as initiation of
diuretics, ultrafiltration, or medications, such as midodrine,
with no evidence that these interventions reduce perioperative risk.
Management of POPH
The heterogeneity in terms of clinical practice and medications used to treat POPH reflects how little is known about
optimal management of this disease. Patients with POPH have
been excluded from almost all clinical trials of PAH therapy
and providers are left to guess based on their prior experience how to approach treatment of POPH. For uncommon
disease such as POPH, more published data are needed from
both clinical trials as well as real-world experience in order to
improve and standardize care.
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Limitations
There are several important limitations to our study. First,
our results may not be generalizable to smaller transplant
centers that perform <50 LTs per year or centers in countries
outside the United States, as they were not included in the
survey. Similarly, our results may not reflect the attitudes and
practice of other providers involved in the management of
patients with POPH, such as transplant surgeons and anesthesiologists. We intended to include transplant surgeons but
did not due to the low response rate and likelihood of bias.
These specialists likely have a unique perspective, particularly
regarding perioperative and intraoperative management. We
also did not have data from nonresponders to further explore
factors that may have impacted response rates and results.
Last, our sample size was small and may not accurately reflect
national practice due to the low response rate and limitations that apply to the nature of the study, such as recall bias,
response bias, and sampling error.

SUMMARY
In summary, the results of this multidisciplinary survey suggest that there is significant variability in provider attitudes
and practice patterns across the country regarding the management of POPH and the role of LT. We also found marked
discordance between published guidelines and provider attitudes and clinical practice. This study highlights the need for
multicenter prospective studies to address current evidence
gaps in POPH and for improved implementation of practice guidelines in order to standardize care for these complex
patients.
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